Lifastuzumab vedotin

Lifastuzumab vedotin
Monoclonal antibody
Type	?
Source	Humanized (from mouse)
Target	phosphate-sodium cotransporter
Clinical data
Other names	DNIB0600A
ATC code	none;
Identifiers
CAS Number	1401812-88-1;
ChemSpider	none;
UNII	7IUT83FK6S;
KEGG	D11238;
Chemical and physical data
Formula	C6504H10028N1744O2018S46
Molar mass	146416.72 g·mol−1

Lifastuzumab vedotin (INN;^[1] development code DNIB0600A) is an experimental monoclonal antibody-drug conjugate designed for the treatment of cancer.^[2]

This drug was developed by Genentech/Roche.

References

[1]

[2]